ArticleThe American journal of surgical pathology2012
Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics.
Article in The American journal of surgical pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.The American journal of gastroenterology · 2015Guideline
- Serrated Polyposis Syndrome: A Narrative Review from Clinical Recognition to Risk-Adapted Cancer Prevention.International journal of general medicine · 2026Review
- Waist Circumference, a Body Shape Index, and Molecular Subtypes of Colorectal Cancer: A Pooled Analysis of Four Cohort Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Intratumoral presence of the genotoxic gut bacteria pksBritish journal of cancer · 2024Article
- Feasibility and Safety of Endoscopic Control for Patients with Serrated Polyposis Syndrome.Digestive diseases (Basel, Switzerland) · 2024Article
- Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome.Journal of gastroenterology · 2022Article
- Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS): results of a multicenter study by the SPS Study Group in Japan.Journal of gastroenterology · 2022Article
- Review
- An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Review
- Management of Serrated Polyps of the Colon.Current treatment options in gastroenterology · 2018Review
- Serrated polyposis: the problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer.Translational cancer research · 2017Article
- Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.The American journal of gastroenterology · 2017Review
- [Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis].Der Pathologe · 2017Review
- Review
- The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis.The journal of pathology. Clinical research · 2016Review
- Sessile serrated polyps: detection, eradication, and prevention of the evil twin.Current treatment options in gastroenterology · 2015Article
- Clinical management of hereditary colorectal cancer syndromes.Nature reviews. Gastroenterology & hepatology · 2015Review
- Clinicopathological Characteristics of Serrated Polyposis Syndrome in Korea: Single Center Experience.Gastroenterology research and practice · 2015Article
- IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.World journal of gastroenterology · 2014Article
- RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
Abstract
Serrated polyposis syndrome (SPS), also known as hyperplastic polyposis, is a syndrome of unknown genetic basis defined by the occurrence of multiple serrated polyps in the large intestine and associated with an increased risk of colorectal cancer (CRC). There are a variety of SPS presentations, which may encompass a continuum of phenotypes modified by environmental and genetic factors. To explore the phenotype of SPS, we recorded the histologic and molecular characteristics of multiple colorectal polyps in patients with SPS recruited between 2000 and 2010 from genetics clinics in Australia, New Zealand, Canada, and the United States. Three specialist gastrointestinal pathologists reviewed the polyps, which they classified into conventional adenomas or serrated polyps, with various subtypes, according to the current World Health Organization criteria. Mutations in BRAF and KRAS and mismatch repair protein expression were determined in a subset of polyps. A total of 100 patients were selected for the study, of whom 58 were female and 42 were male. The total polyp count per patient ranged from 6 to 150 (median 30). The vast majority of patients (89%) had polyposis affecting the entire large intestine. From this cohort, 406 polyps were reviewed. Most of the polyps (83%) were serrated polyps: microvesicular hyperplastic polyps (HP) (n=156), goblet cell HP (n=25), sessile serrated adenoma/polyps (SSA/P) (n=110), SSA/P with cytologic dysplasia (n=28), and traditional serrated adenomas (n=18). A further 69 polyps were conventional adenomas. BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%). Four of 6 SSA/Ps with high-grade dysplasia showed loss of MLH1/PMS2 expression. CRC was diagnosed in 39 patients who were more often found to have a conventional adenoma compared with patients without CRC (P=0.003). Patients with SPS referred to genetics clinics had a pancolonic disease with a high polyp burden and a high rate of BRAF mutation. The occurrence of CRC was associated with the presence of conventional adenoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.